Landscape of Approved and Upcoming PSMA Imaging Agents “Presentation” – Amir Iravani
At the 2025 UCSF-UCLA PSMA Conference, Amir Iravani compares FDA-approved PSMA PET agents (gallium-68 PSMA-11, DCFPyL, rhPSMA-7.3) for prostate cancer imaging. Dr. Iravani notes similar specificity and modest sensitivity for lymph node detection. He questions the need for multiple trials per agent, emphasizing quality interpretation through standardized reporting matters more than which tracer…